Get the Stockscreener App
2.48
6.44%
0.15
In 8 Bio Inc stock is traded at $2.48, with a volume of 30,990.
It is up +6.44% in the last 24 hours and up +60.00% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.33
Open:
$2.36
24h Volume:
30,990
Relative Volume:
0.12
Market Cap:
$24.22M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-3.3067
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
+6.90%
1M Performance:
+60.00%
6M Performance:
+4.64%
1Y Performance:
-67.92%
1-Day Range:
$2.31
$2.53
1-Week Range:
$2.265
$2.73
52-Week Range:
$1.17
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.48 | 22.76M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance UK
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - Stock Titan
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Layoff Tracker: Takeda Slashes US Headcount, Hitting Neuro Commercial Teams Hard - BioSpace
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
GRI Bio (NASDAQ: GRI) approves reverse split to support Nasdaq equity - Stock Titan
KALA Stock Price, Forecast & Analysis | KALA BIO INC (NASDAQ:KALA) - Chartmill
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Cabaletta Bio, Inc. Announces 2026 Strategic Priorities - TradingView — Track All Markets
Zura Bio Ltd Announces Corporate and Clinical Updates for 2026 - TradingView — Track All Markets
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can Boundless Bio Inc. stock double in next 5 yearsPortfolio Return Report & Expert Verified Movement Alerts - Улправда
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - Улправда
Is Mustang Bio Inc. stock positioned for long term growthQuarterly Trade Review & Growth-Oriented Investment Plans - ulpravda.ru
Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting - WV News
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - TradingView — Track All Markets
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
New drug trials target lupus and kidney disease, with 2026 data ahead - Stock Titan
Climb Bio (NASDAQ: CLYM) details 2026 pipeline plans and cash runway into 2028 - Stock Titan
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
FibroGen (NASDAQ: FGEN) rebrands as Kyntra Bio with new ticker KYNB - Stock Titan
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
How a $2 million payment wiped out $10.6 million in company debt - Stock Titan
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development - Quantisnow
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Why GRI Bio Inc. stock remains on buy listsShare Buyback & Stepwise Trade Signal Implementation - Улправда
How sustainable is TELA Bio Inc. stock dividend payout2025 Pullback Review & Low Risk High Win Rate Picks - Улправда
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Third Harmonic Bio Inc. stock withstand economic slowdownTrade Risk Assessment & Reliable Entry Point Alerts - Улправда
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
BioCardia (NASDAQ: BCDA) moves to PMDA consultation on heart failure therapy - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):